| The prevalence, correlates and treatment of pain in the European Union PC Langley Current medical research and opinion 27 (2), 463-480, 2011 | 277 | 2011 |
| The prevalence, correlates and treatment of pain in Spain PC Langley, MA Ruiz-Iban, JT Molina, J De Andres, JRGE Castellón Journal of medical economics 14 (3), 367-380, 2011 | 179 | 2011 |
| The burden associated with neuropathic pain in Western Europe PC Langley, C Van Litsenburg, JC Cappelleri, D Carroll Journal of medical economics 16 (1), 85-95, 2013 | 162 | 2013 |
| The impact of pain on labor force participation, absenteeism and presenteeism in the European Union P Langley, G Müller-Schwefe, A Nicolaou, H Liedgens, J Pergolizzi, ... Journal of medical economics 13 (4), 662-672, 2010 | 160 | 2010 |
| The societal impact of pain in the European Union: health-related quality of life and healthcare resource utilization P Langley, G Müller-Schwefe, A Nicolaou, H Liedgens, J Pergolizzi, ... Journal of medical economics 13 (3), 571-581, 2010 | 156 | 2010 |
| A review of cost-of-illness studies on obesity MA Kortt, PC Langley, ER Cox Clinical therapeutics 20 (4), 772-779, 1998 | 148 | 1998 |
| Humanistic and economic impacts of hepatitis C infection in the United States MD DiBonaventura, JS Wagner, Y Yuan, G L'Italien, P Langley, ... Journal of Medical Economics 13 (4), 709-718, 2010 | 97 | 2010 |
| Risperidone versus haloperidol: II. Cost-effectiveness A Davies, PC Langley, NA Keks, SV Catts, T Lambert, I Schweitzer Clinical therapeutics 20 (1), 196-213, 1998 | 95 | 1998 |
| The November 1995 revised Australian guidelines for the economic evaluation of pharmaceuticals PC Langley Pharmacoeconomics 9, 341-352, 1996 | 73 | 1996 |
| The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities MD Dibonaventura, JS Wagner, Y Yuan, G L’Italien, P Langley, ... Journal of Medical Economics 14 (2), 253-261, 2011 | 72 | 2011 |
| Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain PC Langley, AD Patkar, KA Boswell, CJ Benson, JR Schein Current Medical Research and Opinion 26 (1), 239-251, 2010 | 68 | 2010 |
| The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan GG Liu, M daCosta DiBonaventura, Y Yuan, JS Wagner, JL Gilbert, ... Value in Health 15 (1), S65-S71, 2012 | 66 | 2012 |
| Cost-effectiveness of regional poison control centers DL Harrison, JLR Draugalis, MK Slack, PC Langley Archives of internal medicine 156 (22), 2601-2608, 1996 | 64 | 1996 |
| The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts. PC Langley, SK Tyring, MH Smith The American Journal of Managed Care 5 (1), 69-77, 1999 | 59 | 1999 |
| Disease management programs EP Armstrong, PC Langley American journal of health-system pharmacy 53 (1), 53-58, 1996 | 53 | 1996 |
| Pain, health related quality of life and healthcare resource utilization in Spain P Langley, C Pérez Hernández, C Margarit Ferri, D Ruiz Hidalgo, ... Journal of medical economics 14 (5), 628-638, 2011 | 52 | 2011 |
| Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement DW Hawkins, PC Langley, KP Krueger American journal of health-system pharmacy 54 (10), 1185-1190, 1997 | 51 | 1997 |
| The societal burden of pain in Germany: health-related quality-of-life, health status and direct medical costs PC Langley Journal of medical economics 15 (6), 1201-1215, 2012 | 48 | 2012 |
| The costs of treating external genital warts in England and Wales: a treatment pattern analysis PC Langley, DJ White, SM Drake International journal of STD & AIDS 15 (8), 501-508, 2004 | 47 | 2004 |
| Nonsense on Stilts–Part 1: The ICER 2020-2023 value assessment framework for constructing imaginary worlds PC Langley INNOVATIONS in pharmacy 11 (1), 2020 | 46 | 2020 |
